Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin to Construct Biopharmaceutical API Manufacturing Facility
October 25, 2012
- Ono Ties Up with Domain Therapeutics of France for GPCR-Based Drug Discovery
October 25, 2012
- ZOLL Medical Acquired by Asahi Kasei Last Year Establishes Japanese Subsidiary
October 25, 2012
- Fujifilm, Kyowa Kirin to Develop Avastin Biosimilar
October 25, 2012
- “Changing Way of Thinking Necessary among Industry, Government, Academia for Promotion of Drug Discovery”: AZ Chairman Kato
October 25, 2012
- Santen Going on Offensive in Growth Fields in Ophthalmology
October 24, 2012
- More Products, Fewer Facilities Per MR: Novartis Introduces New Marketing System
October 24, 2012
- Kaken Pharmaceutical Files NDA for Efinaconazole, 1st Topical Drug for Onychomycosis in Japan
October 24, 2012
- Former Nycomed CSO to Head General Medicine Drug Discovery Unit of Takeda
October 24, 2012
- COPD Treatment Market to Expand 2.8 Times by 2020 Compared to 2011: Fuji-Keizai
October 24, 2012
- Antiepileptic Drug Fycompa Approved in the US: Eisai
October 24, 2012
- Astellas Launches Mirabegron in US
October 24, 2012
- Astellas Poised for Domestic PIIb Trial of Novel IBS Treatment
October 23, 2012
- Astellas Receives Recommendation for Approval of Mirabegron in Europe
October 23, 2012
- Neuropathic Pain Treatment Offered Funding from JST’s Support Program: Nippon Chemiphar
October 23, 2012
- Astellas Launches Gonax for Full-Fledged Entry into Cancer Field
October 23, 2012
- Takeda Moves Up to 5th, Pfizer 1st in Patent Assets Ranking
October 22, 2012
- Chugai Succeeds in Establishing World's First Stable Cancer Stem Cell Lines
October 22, 2012
- MTPC to Dissolve Capital Alliance with Choseido
October 22, 2012
- Kyowa Kirin Suspends PIIa Study of RTA 402 in Response to Licensor’s Termination of Study
October 22, 2012
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…